Abstract 922P
Background
Genomic instability is an hallmark of cancer that has been associated to immune evasion, cancer progression and multidrug resistance. MOSCATO (NCT) was a prospective clinical trial evaluating the clinical benefit of high-throughput genomic analyses in patients with advanced solid tumors. In this study we investigated a genomic instability score based on somatic copy number alterations as determined by Single Nucleotide Polymorphism (SNP) array as a biomarker for head and neck cancer patients.
Methods
Extracted DNA from fresh frozen tumor was analyzed using high-resolution Affymetrix Cytoscan® HD array whereas extracted DNA from FFPE samples was analyzed using the Affymetrix Oncoscan® CNV assay. The absolute copy-number (ACN) profile was generated by ASCAT v3.1 through EaCoN v0.3.6 (https://github.com/gustaveroussy/EaCoN, PMID 36669143) on R v4.1.1 and then the genomic instability score (GIS) was estimated as the sum of the segment length multiplied by the absolute difference between segment copy number and the ASCAT estimated sample ploidy. This sum is reported to the reference genome length. In parallel, somatic mutation were assessed with a NGS panel covering including at least 75 critical oncogenes and tumor suppressor genes.
Results
SNP array data were available for 58 patients out of the 111 with head and neck cancers. 38 were men, 34 had squamous histology (SCC), 13 cystadenocarcinoma (ACC) and 11 other types (adenocarcinoma, mucinous carcinoma). Patients with SCC had higher GIS (median 0.53 for SCC vs 0.05 for ACC and 0.40 for others). At genomic level, the presence of TP53 (p < 0.001) and ATM (p 0.056) were associated with higher GIS. This was confirmed also after adjusting for histology. Conversely, GIS score was not associated with age. Patients with SCC that were positive for HPV (n=11) had lower GIS respect to HPV negatives (n=14, 0.24 vs 0.85, p 0.05) Higher GIS score was associated with decreased OS after adjusting for histology (HR 1.87, 95% CI 1.31 - 2.65, p < 0.001).
Conclusions
Genomic instability score based on SNP array copy number alterations profile is associated with worse prognosis in patients with carcinoma of the head and neck. Higher GIS score is found in squamous cell carcinomas and is associated with mutations in genes involved in cell cycle control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1056P - Real-world usage and adverse events (AE) of immune checkpoint inhibitors (ICI): A large-scale, automated, GDPR-compliant analysis of hospital records
Presenter: Annelies Verbiest
Session: Poster session 03
1057P - Blinded independent central review versus local investigator assessment of progression-free survival in randomized controlled trials of immunotherapy in advanced cancers: A systematic review and meta-analysis
Presenter: Simeone D'Ambrosio
Session: Poster session 03
1058P - Hyperprogressive disease during immune checkpoint inhibitor: A cloudy phenomenon with real consequences
Presenter: Damien Bruyat
Session: Poster session 03
1059P - Association between tumor longevity and immune-checkpoint inhibitor outcomes: A retrospective study in head and neck, lung, renal/urothelial cancers
Presenter: Rebecca Romanò
Session: Poster session 03
1060P - Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: A metrology informatics analysis based on machine learning
Presenter: Song-Bin Guo
Session: Poster session 03
1061P - Assessing differential informative censoring in control and experimental arm in trials testing immunotherapy in metastatic cancers: A systematic review
Presenter: Filippo Vitale
Session: Poster session 03
1062P - Effect of the immunological circadian rhythm on the treatment of locally advanced non-small cell lung cancer treated with consolidation immunotherapy
Presenter: Èlia Sais
Session: Poster session 03
1063P - Influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohort
Presenter: Víctor Albarrán Fernández
Session: Poster session 03